Zanzalintinib for kidney cancer that spread to bone
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called zanzalintinib for people with advanced clear cell kidney cancer that has spread to the bones (at least 3 spots). The study wants to see if this drug can help slow down or shrink the cancer. It's for patients who have already had some prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced clear cell kidney cancer that has spread to at least 3 places in your bones, and at least one of those bone spots is not getting radiation.
- You must have had 1 to 3 prior treatments for your cancer, including either an immunotherapy combination or a targeted therapy combination.
- You need to have seen a dentist within the last 90 days and gotten clearance to receive bone-strengthening medication.
- Your overall health should be reasonably good (ECOG score 0-2) and your blood tests must show that your organs (kidneys, liver, blood counts) are working well enough.
- You cannot have untreated or unstable brain metastases, major bleeding problems, or serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
This trial tests new drug combinations for people with advanced kidney cancer whose disease returned after a prior immunotherapy. It's designed to find better treatment options for those who have not received other treatments for advanced disease.
This study tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that has not responded well to other treatments. The goal is to see if the combination slows down cancer growth.
This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.
This trial tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that returned after or within 2 years of finishing an immunotherapy treatment after surgery. You cannot have received any other cancer treatments besides that immunotherapy.
Hear when a new Clear Cell Renal Cell Cancer (ccRCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.